A Study of ANX009 in Adult Participants With Lupus Nephritis

Key Inclusion Criteria:

• Participants who have a diagnosis of SLE according to European League AgainstRheumatism/American College of Rheumatology (EULAR/ACR) 2019 Criteria

• Has a history of International Society of Nephrology/Renal Pathology Society (ISN/RPS) Class III or IV with or without Class V glomerulonephritis on renal biopsywithin 24 months prior to screening or as performed during screening.

• Has proteinuria level between ≥0.5 to 3.0 grams (g)/g/day assessed via urine proteinto creatine ratio (UPCR) during screening.

• Has evidence of classical complement activation at screening

• Has a history of receiving one or more standard therapies for LN

Key Exclusion Criteria:

• Has a history of ISN/RPS Class VI or isolated Class V (withoutco-existent/predominant Class III or IV glomerulonephritis) glomerulonephritis onrenal biopsy.

• Has severe kidney disease defined as eGFR of <30 milliliters (mL)/minute/1.73 squaremeter (m^2) or end-stage renal disease (ESRD) requiring dialysis or kidneytransplantation.

• Has a concurrent systemic autoimmune disease that may confound study assessmentsother than SLE, LN, or cutaneous lupus erythematosus.

NOTE: Other inclusion and/or exclusion criteria may apply.